{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:23:13Z","timestamp":1785338593322,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009414","name":"Istituto Oncologico Veneto","doi-asserted-by":"publisher","award":["5X1000 2016 Agon"],"award-info":[{"award-number":["5X1000 2016 Agon"]}],"id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009414","name":"Istituto Oncologico Veneto","doi-asserted-by":"publisher","award":["5\u00d71000 Cancerplat-2"],"award-info":[{"award-number":["5\u00d71000 Cancerplat-2"]}],"id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["RETE-NET 2016-2361632"],"award-info":[{"award-number":["RETE-NET 2016-2361632"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["GR-2016-02361019"],"award-info":[{"award-number":["GR-2016-02361019"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-99153-y","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T03:12:48Z","timestamp":1746155568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A model workflow for microfluidic enrichment and genetic analysis of circulating melanoma cells"],"prefix":"10.1038","volume":"15","author":[{"given":"Cristina","family":"Poggiana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Francesco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Catoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Gallingani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Piccin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Aneloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Salizzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Pigozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Fabozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Menin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"del Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mocellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion-Sileni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Scaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"99153_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.33393\/jcb.2023.2629","volume":"12","author":"A Templeman","year":"2023","unstructured":"Templeman, A. et al. Analytical performance of the FDA-cleared Parsortix\u00ae PC1 system. J. Circ. Biomark. 12, 26\u201333 (2023).","journal-title":"J. Circ. Biomark."},{"key":"99153_CR2","doi-asserted-by":"crossref","unstructured":"Gorges, K. et al. Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. Cancers 11, (2019).","DOI":"10.3390\/cancers11111685"},{"key":"99153_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","volume":"21","author":"SN Lone","year":"2022","unstructured":"Lone, S. N. et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol. Cancer. 21, 79 (2022).","journal-title":"Mol. Cancer"},{"key":"99153_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-021-00048-x","volume":"2","author":"MJ de Lange","year":"2021","unstructured":"de Lange, M. J., Nell, R. J. & van der Velden, P. A. Scientific and clinical implications of genetic and cellular heterogeneity in uveal melanoma. Mol. Biomed. 2, 25 (2021).","journal-title":"Mol. Biomed."},{"key":"99153_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.molonc.2016.01.009","volume":"10","author":"K Pantel","year":"2016","unstructured":"Pantel, K. & Alix-Panabi\u00e8res, C. Liquid biopsy: potential and challenges. Mol. Oncol. 10, 371\u2013373 (2016).","journal-title":"Mol. Oncol."},{"key":"99153_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531\u2013548 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"99153_CR7","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/cancers12092361","volume":"12","author":"R Agashe","year":"2020","unstructured":"Agashe, R. & Kurzrock, R. Circulating tumor cells: from the laboratory to the Cancer clinic. Cancers 12, 2361 (2020).","journal-title":"Cancers"},{"key":"99153_CR8","doi-asserted-by":"crossref","unstructured":"Kong, S. L. Complementary sequential Circulating tumor cell (CTC) and cell-Free tumor DNA (ctDNA) profiling reveals metastatic heterogeneity and genomic changes in lung Cancer and breast Cancer. Front. Oncol. 11, (2021).","DOI":"10.3389\/fonc.2021.698551"},{"key":"99153_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res, C. & Pantel, K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 11, 858\u2013873 (2021).","journal-title":"Cancer Discov"},{"key":"99153_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast Cancer. N Engl. J. Med. 351, 781\u2013791 (2004).","journal-title":"N Engl. J. Med."},{"key":"99153_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41416-020-0750-9","volume":"122","author":"CA Aya-Bonilla","year":"2020","unstructured":"Aya-Bonilla, C. A. et al. Detection and prognostic role of heterogeneous populations of melanoma Circulating tumour cells. Br. J. Cancer. 122, 1059\u20131067 (2020).","journal-title":"Br. J. Cancer"},{"key":"99153_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2022.03.013","volume":"84","author":"A Markou","year":"2022","unstructured":"Markou, A., Tzanikou, E. & Lianidou, E. The potential of liquid biopsy in the management of cancer patients. Semin Cancer Biol. 84, 69\u201379 (2022).","journal-title":"Semin Cancer Biol."},{"key":"99153_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13046-020-01601-2","volume":"39","author":"M Russano","year":"2020","unstructured":"Russano, M. et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J. Exp. Clin. Cancer Res. 39, 95 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"99153_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jamcollsurg.2018.04.026","volume":"227","author":"CS Hall","year":"2018","unstructured":"Hall, C. S. et al. Circulating tumor cells in stage IV melanoma patients. J. Am. Coll. Surg. 227, 116\u2013124 (2018).","journal-title":"J. Am. Coll. Surg."},{"key":"99153_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-023-00492-8","volume":"8","author":"MC Scaini","year":"2024","unstructured":"Scaini, M. C. et al. A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance. Npj Precis Oncol. 8, 1\u201316 (2024).","journal-title":"Npj Precis Oncol."},{"key":"99153_CR16","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/jid.2012.468","volume":"133","author":"L Khoja","year":"2013","unstructured":"Khoja, L. et al. Biomarker utility of Circulating tumor cells in metastatic cutaneous melanoma. J. Invest. Dermatol. 133, 1582\u20131590 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"99153_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/annonc\/mdu207","volume":"26","author":"L Khoja","year":"2015","unstructured":"Khoja, L., Lorigan, P., Dive, C., Keilholz, U. & Fusi, A. Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. Ann. Oncol. Off J. Eur. Soc. Med. Oncol. 26, 33\u201339 (2015).","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"key":"99153_CR18","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-19-2670","volume":"26","author":"A Lucci","year":"2020","unstructured":"Lucci, A. et al. Circulating tumor cells and early relapse in Node-positive melanoma. Clin. Cancer Res. Off J. Am. Assoc. Cancer Res. 26, 1886\u20131895 (2020).","journal-title":"Clin. Cancer Res. Off J. Am. Assoc. Cancer Res."},{"key":"99153_CR19","doi-asserted-by":"crossref","unstructured":"Reid, A. L., Freeman, J. B., Millward, M., Ziman, M. & Gray, E. S. Detection of BRAF-V600E and V600K in melanoma Circulating tumour cells by droplet digital PCR. Clin. Biochem. (2015).","DOI":"10.1016\/j.clinbiochem.2014.12.007"},{"key":"99153_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/cancers11020157","volume":"11","author":"C Aya-Bonilla","year":"2019","unstructured":"Aya-Bonilla, C. et al. Immunomagnetic-Enriched subpopulations of melanoma Circulating tumour cells (CTCs) exhibit distinct transcriptome profiles. Cancers 11, 157 (2019).","journal-title":"Cancers"},{"key":"99153_CR21","doi-asserted-by":"publisher","first-page":"78890","DOI":"10.18632\/oncotarget.20354","volume":"8","author":"AC McEvoy","year":"2017","unstructured":"McEvoy, A. C. et al. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget 8, 78890\u201378900 (2017).","journal-title":"Oncotarget"},{"key":"99153_CR22","doi-asserted-by":"publisher","first-page":"67355","DOI":"10.18632\/oncotarget.18641","volume":"8","author":"CA Aya-Bonilla","year":"2017","unstructured":"Aya-Bonilla, C. A. et al. Isolation and detection of Circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget 8, 67355\u201367368 (2017).","journal-title":"Oncotarget"},{"key":"99153_CR23","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1073\/pnas.1719264115","volume":"115","author":"X Hong","year":"2018","unstructured":"Hong, X. et al. Molecular signatures of Circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc. Natl. Acad. Sci. 115, 2467\u20132472 (2018).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"99153_CR24","doi-asserted-by":"publisher","first-page":"e0138032","DOI":"10.1371\/journal.pone.0138032","volume":"10","author":"L Xu","year":"2015","unstructured":"Xu, L. et al. Optimization and evaluation of a novel size based Circulating tumor cell isolation system. PLOS ONE. 10, e0138032 (2015).","journal-title":"PLOS ONE"},{"key":"99153_CR25","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cyto.a.23571","volume":"93","author":"MC Miller","year":"2018","unstructured":"Miller, M. C., Robinson, P. S., Wagner, C. & O\u2019Shannessy, D. J. The Parsortix\u2122 cell separation System\u2014A versatile liquid biopsy platform. Cytometry A. 93, 1234\u20131239 (2018).","journal-title":"Cytometry A"},{"key":"99153_CR26","first-page":"755","volume":"38","author":"C Rao","year":"2011","unstructured":"Rao, C. et al. Circulating melanoma cells and survival in metastatic melanoma. Int. J. Oncol. 38, 755\u2013760 (2011).","journal-title":"Int. J. Oncol."},{"key":"99153_CR27","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.3390\/cancers14174153","volume":"14","author":"C Catoni","year":"2022","unstructured":"Catoni, C. et al. Investigating the retained inhibitory effect of Cobimetinib against p.P124L mutated MEK1: A combined liquid biopsy and in Silico approach. Cancers 14, 4153 (2022).","journal-title":"Cancers"},{"key":"99153_CR28","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12864-017-3770-y","volume":"18","author":"AR Buckley","year":"2017","unstructured":"Buckley, A. R. et al. Pan-cancer analysis reveals technical artifacts in TCGA germline variant calls. BMC Genom. 18, 458 (2017).","journal-title":"BMC Genom."},{"key":"99153_CR29","doi-asserted-by":"publisher","first-page":"56066","DOI":"10.18632\/oncotarget.10701","volume":"8","author":"A Babayan","year":"2016","unstructured":"Babayan, A. et al. Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. Oncotarget 8, 56066\u201356080 (2016).","journal-title":"Oncotarget"},{"key":"99153_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41467-022-28115-z","volume":"13","author":"JQ Lim","year":"2022","unstructured":"Lim, J. Q., Lim, S. T. & Ong, C. K. Misaligned sequencing reads from the GNAQ-pseudogene locus May yield GNAQ artefact variants. Nat. Commun. 13, 458 (2022).","journal-title":"Nat. Commun."},{"key":"99153_CR31","doi-asserted-by":"publisher","first-page":"e0116371","DOI":"10.1371\/journal.pone.0116371","volume":"10","author":"M Versluis","year":"2015","unstructured":"Versluis, M. et al. Digital PCR validates 8q dosage as prognostic tool in uveal melanoma. PloS One. 10, e0116371 (2015).","journal-title":"PloS One"},{"key":"99153_CR32","doi-asserted-by":"publisher","first-page":"37824","DOI":"10.18632\/oncotarget.5637","volume":"6","author":"MJ de Lange","year":"2015","unstructured":"de Lange, M. J. et al. Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma. Oncotarget 6, 37824\u201337835 (2015).","journal-title":"Oncotarget"},{"key":"99153_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10120-016-0599-z","volume":"20","author":"K Shoda","year":"2017","unstructured":"Shoda, K. et al. Monitoring the HER2 copy number status in Circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer. 20, 126\u2013135 (2017).","journal-title":"Gastric Cancer"},{"key":"99153_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1479-5876-10-192","volume":"10","author":"JB Freeman","year":"2012","unstructured":"Freeman, J. B., Gray, E. S., Millward, M., Pearce, R. & Ziman, M. Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of Circulating melanoma cells. J. Transl Med. 10, 192 (2012).","journal-title":"J. Transl Med."},{"key":"99153_CR35","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray, E. S. et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6, 42008\u201342018 (2015).","journal-title":"Oncotarget"},{"key":"99153_CR36","doi-asserted-by":"publisher","first-page":"853","DOI":"10.5858\/2009-0717-RAR.1","volume":"135","author":"VG Prieto","year":"2011","unstructured":"Prieto, V. G. & Shea, C. R. Immunohistochemistry of melanocytic proliferations. Arch. Pathol. Lab. Med. 135, 853\u2013859 (2011).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"99153_CR37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1373\/clinchem.2008.116467","volume":"55","author":"M Kitago","year":"2009","unstructured":"Kitago, M. et al. mRNA expression and BRAF mutation in Circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin. Chem. 55, 757\u2013764 (2009).","journal-title":"Clin. Chem."},{"key":"99153_CR38","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1083\/jcb.200403174","volume":"165","author":"J Yang","year":"2004","unstructured":"Yang, J. et al. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J. Cell. Biol. 165, 881\u2013891 (2004).","journal-title":"J. Cell. Biol."},{"key":"99153_CR39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s004280050362","volume":"434","author":"AA Jungbluth","year":"1999","unstructured":"Jungbluth, A. A. et al. Expression of melanocyte-associated markers gp-100 and Melan-A\/MART-1 in angiomyolipomas. Virchows Arch. 434, 429\u2013435 (1999).","journal-title":"Virchows Arch."},{"key":"99153_CR40","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.bone.2008.05.001","volume":"43","author":"T Matsumoto","year":"2008","unstructured":"Matsumoto, T. et al. Circulating endothelial\/skeletal progenitor cells for bone regeneration and healing. Bone 43, 434\u2013439 (2008).","journal-title":"Bone"},{"key":"99153_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0008-8749(92)90008-D","volume":"143","author":"E Braakman","year":"1992","unstructured":"Braakman, E., van de Winkel, J. G. J., van Krimpen, B. A., Jansze, M. & Bolhuis, R. L. H. CD16 on human \u0393\u03b4 T lymphocytes: expression, function, and specificity for mouse IgG isotypes. Cell. Immunol. 143, 97\u2013107 (1992).","journal-title":"Cell. Immunol."},{"key":"99153_CR42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/clinchem\/hvaa322","volume":"67","author":"RPL Neves","year":"2021","unstructured":"Neves, R. P. L. et al. Proficiency testing to assess technical performance for CTC-Processing and detection methods in CANCER-ID. Clin. Chem. 67, 631\u2013641 (2021).","journal-title":"Clin. Chem."},{"key":"99153_CR43","doi-asserted-by":"publisher","first-page":"101258","DOI":"10.1016\/j.mam.2024.101258","volume":"96","author":"DJ Smit","year":"2024","unstructured":"Smit, D. J. & Pantel, K. Circulating tumor cells as liquid biopsy markers in cancer patients. Mol. Aspects Med. 96, 101258 (2024).","journal-title":"Mol. Aspects Med."},{"key":"99153_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/ijc.32092","volume":"145","author":"K Weidele","year":"2019","unstructured":"Weidele, K. et al. Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples. Int. J. Cancer. 145, 232\u2013241 (2019).","journal-title":"Int. J. Cancer"},{"key":"99153_CR45","doi-asserted-by":"publisher","first-page":"17501","DOI":"10.1038\/s41598-024-68336-4","volume":"14","author":"C L\u00f8ppke","year":"2024","unstructured":"L\u00f8ppke, C. et al. Combined microfluidic enrichment and staining workflow for single-cell analysis of Circulating tumor cells in metastatic prostate cancer patients. Sci. Rep. 14, 17501 (2024).","journal-title":"Sci. Rep."},{"key":"99153_CR46","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/14737159.2016.1255144","volume":"16","author":"JF Swennenhuis","year":"2016","unstructured":"Swennenhuis, J. F., van Dalum, G., Zeune, L. L. & Terstappen, L. W. M. M. Improving the CellSearch\u00ae system. Expert Rev. Mol. Diagn. 16, 1291\u20131305 (2016).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"99153_CR47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel, K. & Alix-Panabi\u00e8res, C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat. Rev. Clin. Oncol. 16, 409\u2013424 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"99153_CR48","doi-asserted-by":"publisher","first-page":"9714","DOI":"10.3390\/ijms22189714","volume":"22","author":"P Kami\u0144ska","year":"2021","unstructured":"Kami\u0144ska, P. et al. Liquid biopsy in melanoma: significance in diagnostics, prediction and treatment monitoring. Int. J. Mol. Sci. 22, 9714 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"99153_CR49","doi-asserted-by":"publisher","first-page":"175883592090541","DOI":"10.1177\/1758835920905415","volume":"12","author":"M Tucci","year":"2020","unstructured":"Tucci, M. et al. Dual-procedural separation of CTCs in cutaneous melanoma provides useful information for both molecular diagnosis and prognosis. Ther. Adv. Med. Oncol. 12, 1758835920905415 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"99153_CR50","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/s44321-024-00082-6","volume":"16","author":"M Sementsov","year":"2024","unstructured":"Sementsov, M. et al. Mutation analysis in individual Circulating tumor cells depicts intratumor heterogeneity in melanoma. EMBO Mol. Med. 16, 1560\u20131578 (2024).","journal-title":"EMBO Mol. Med."},{"key":"99153_CR51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabi\u00e8res","year":"2016","unstructured":"Alix-Panabi\u00e8res, C. & Pantel, K. Clinical applications of Circulating tumor cells and Circulating tumor DNA as liquid biopsy. Cancer Discov. 6, 479\u2013491 (2016).","journal-title":"Cancer Discov"},{"key":"99153_CR52","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","volume":"51","author":"AH Shain","year":"2019","unstructured":"Shain, A. H. et al. The genetic evolution of metastatic uveal melanoma. Nat. Genet. 51, 1123\u20131130 (2019).","journal-title":"Nat. Genet."},{"key":"99153_CR53","doi-asserted-by":"publisher","first-page":"102091","DOI":"10.1016\/j.ctrv.2020.102091","volume":"90","author":"BH Louie","year":"2020","unstructured":"Louie, B. H. & Kurzrock, R. BAP1: not just a BRCA1-associated protein. Cancer Treat. Rev. 90, 102091 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"99153_CR54","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41588-024-01799-3","volume":"56","author":"AJ Waters","year":"2024","unstructured":"Waters, A. J. et al. Saturation genome editing of BAP1 functionally classifies somatic and germline variants. Nat. Genet. 56, 1434\u20131445 (2024).","journal-title":"Nat. Genet."},{"key":"99153_CR55","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410 (2010).","journal-title":"Science"},{"key":"99153_CR56","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1038\/s41467-020-15606-0","volume":"11","author":"J Karlsson","year":"2020","unstructured":"Karlsson, J. et al. Molecular profiling of driver events in metastatic uveal melanoma. Nat. Commun. 11, 1894 (2020).","journal-title":"Nat. Commun."},{"key":"99153_CR57","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-10-2900","volume":"17","author":"H Makishima","year":"2011","unstructured":"Makishima, H. & Maciejewski, J. P. Pathogenesis and consequences of uniparental disomy in Cancer. Clin. Cancer Res. Off J. Am. Assoc. Cancer Res. 17, 3913\u20133923 (2011).","journal-title":"Clin. Cancer Res. Off J. Am. Assoc. Cancer Res."},{"key":"99153_CR58","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1101\/gr.276617.122","volume":"32","author":"KK Takahashi","year":"2022","unstructured":"Takahashi, K. K. & Innan, H. Frequent somatic gene conversion as a mechanism for loss of heterozygosity in tumor suppressor genes. Genome Res. 32, 1017\u20131025 (2022).","journal-title":"Genome Res."},{"key":"99153_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12943-019-0989-z","volume":"18","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. The interplay of Circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. Mol. Cancer. 18, 36 (2019).","journal-title":"Mol. Cancer"},{"key":"99153_CR60","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/cancers16071377","volume":"16","author":"TA Allen","year":"2024","unstructured":"Allen, T. A. The role of Circulating tumor cells as a liquid biopsy for cancer: advances, biology, technical challenges, and clinical relevance. Cancers 16, 1377 (2024).","journal-title":"Cancers"},{"key":"99153_CR61","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/s41416-022-01962-9","volume":"127","author":"D Fernandez-Garcia","year":"2022","unstructured":"Fernandez-Garcia, D. et al. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer. Br. J. Cancer. 127, 1858\u20131864 (2022).","journal-title":"Br. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99153-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:38:53Z","timestamp":1746520733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99153-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["99153"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-99153-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the ISTITUTO ONCOLOGICO VENETO (approval No. CESC-IOV 2018\/36 on April 19, 2018). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"M.C.S. received a travel grant from Agilent Technologies, all the other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15329"}}